 in Patients with Chronic Kidney Disease<br />
<b>Deprecated</b>: urlencode(): Passing null to parameter #1 ($string) of type string is deprecated in <b>/var/www/html/diabetesnews.com/wp-content/themes/dn_default/single.php</b> on line <b>22</b><br />
)
Many patients with chronic kidney disease are at a higher risk for severe kidney and heart health issues. The DAPA-CKD trial was designed to see the impact of Dapagliflozin Propanediol, which is sold under the brand name Farxiga, in patients with and without type 2 diabetes who had chronic kidney disease. Read more